Effect of oral contraceptive therapy on homocysteine and C-reactive protein levels in women: An observational study;Kadınlarda oral kontraseptif tedavisinin homosistein ve C-reaktif protein düzeyleri üzerine etkisi: Gözlemsel bir çalışma

Anadolu Kardiyoloji Dergisi

Volumn 11, Issue 8, 2011, Pages 698-702

  Norouzi, Vajihe ^a   Seifi, Morteza ^a   Fallah, Soudabeh ^a   Korani, Mohsen ^a   Samadikuchaksaraei, Ali ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Atherosclerosis; C reactive protein; Homocysteine; Oral contraceptive pill

Indexed keywords

C REACTIVE PROTEIN; ETHINYLESTRADIOL; HOMOCYSTEINE; LEVONORGESTREL;

ADULT; BODY MASS; C REACTIVE PROTEIN BLOOD LEVEL; CHI SQUARE TEST; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HOMOCYSTEINE BLOOD LEVEL; HUMAN; HUMAN CELL; OBESITY; OBSERVATIONAL STUDY; PILL; PROTEIN BLOOD LEVEL; REVIEW; STUDENT T TEST;

EID: 83455188089     PISSN: 13028723     EISSN: None     Source Type: Journal    
DOI: 10.5152/akd.2011.191     Document Type: Review

References (23)

1. Reuben DB, Palla SL, Hu P, Reboussin BA, Crandall C, Herrington DM, et al. Progestins affect mechanism of estrogen-induced C-reactive protein stimulation. Am J Med 2006; 119: 167. [CrossRef]
2. Krivak TC, Zorn KK. Venous thromboembolism in obstetrics and gynecology. Obstet Gynecol 2007; 109: 761-77. [CrossRef]
3. Cauci S, Di Santolo M, Culhane JF, Stel G, Gonano F, Guaschino S. Effects of third-generation oral contraceptives on high-sensitivity C-reactive protein and homocysteine in young women. Obstet Gynecol 2008; 111: 857-64. [CrossRef]
4. Ridker PM, Silvertown JD. Inflammation, C-reactive protein, and atherothrombosis. J Periodontol 2008; 79(8 Suppl): 1544-51. [CrossRef]
5. Yan J, Liao JK, Wang D. Elevated homocysteine and C-reactive protein levels independently predict worsening prognosis after stroke in Chinese patients. J Huazhong Univ Sci Technolog Med Sci 2010; 30: 643-7. [CrossRef]
6. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-43. [CrossRef]
7. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-54. [CrossRef]
8. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-74. [CrossRef]
9. Raitakari M, Mansikkaniemi K, Marniemi J, Viikari JS, Raitakari OT. Distribution and determinants of serum high-sensitive C-reactive protein in a population of young adults: The Cardiovascular Risk in Young Finns Study. J Intern Med 2005; 258: 428-34. [CrossRef]
10. de Ferranti SD, Gauvreau K, Ludwig DS, Newburger JW, Rifai N. Inflammation and changes in metabolic syndrome abnormalities in US adolescents: findings from the 1988-1994 and 1999-2000 National Health and Nutrition Examination Surveys. Clin Chem 2006; 52: 1325-30. [CrossRef]
11. Casabellata G, Di Santolo M, Banfi G, Stel G, Gonano F, Cauci S. Evaluation of iron deficiency in young women in relation to oral contraceptive use. Contraception 2007; 76: 200-7. [CrossRef]
12. Frantzen F, Faaren AL, Alfheim I, Nordhei AK. Enzyme conversion immunoassay for determining total homocysteine in plasma or serum. Clin Chem 1998; 44: 311-6.
13. Martini MC, Dancisak BB, Haggans CJ, Thomas W, Slavin JL. Effects of soy intake on sex hormone metabolism in premenopausal women. Nutr Cancer 1999; 34: 133-9. [CrossRef]
14. Hak AE, Polderman KH, Westendorf IC, Jakob C, Hoftman A, Witterman JC, et al. Increased plasma homocysteine after menopause. Atherosclerosis 2000: 149: 163-8.
15. Ridker PM. Evaluating novel cardiovascular risk factors: can be we better predict heart attacks? Ann Intern Med 1999; 130: 933-7.
16. Döring A, Fröhlich M, Löwel H, Koenig W. Third generation oral contraceptive use and cardiovascular risk factor. Atherosclerosis 2004; 172: 281-6. [CrossRef]
17. Schueller PO, Feuring M, Sharkova Y, Grimm W, Christ M. Effects of synthetic progestagens on autonomic tone, neurohormons and C-reactive protein levels in young healthy females in reproductive age. Int J Cardiol 2006; 111: 42-8. [CrossRef]
18. Chiantera V, Sarti CD, Fornaro F, Farzati A, Franciscis P, Sepe E, et al. Long-term effects of oral and transdermal hormone replacement therapy on plasma homocysteine levels. Menopause 2003; 10: 286-91. [CrossRef]
19. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998; 97: 2007-11.
20. Van Guelpen B, Hultdin J, Johansson I, Stegmayr B, Hallmans G, Nilsson TK, et al. Folate vitamine B12, and risk of ischemic and hemorrhagic stroke: a prospective, nested case-referent study of plasma concentrations and dietary intake. Stroke 2005; 36: 1426-31. [CrossRef]
21. Cangnacci A, Tirelli A, Renzi A, Paoletti AM, Volpe A. Effects of two different oral contraceptives on homocysteine metabolism in women with polycystic ovary syndrome. Contraception 2006; 73: 348-51. [CrossRef]
22. Tanis BC, Blom HJ, Bloemenkamp DG, van den Bosch MA, Algra A, van der Graaf Y, et al. Folate, homocysteine levels, methylenetrahydrofolate reductase (MTHFR) 677C->T variant, and the risk of myocardial infarction in young women: effect of female hormones on homocysteine levels. J Thromb Haemost 2004; 2: 35-41. [CrossRef]
23. Youssef MY, Mojiminiyi OA, Abdella NA. Plasma concentrations of C-reactive protein and total homocysteine to the severity and risk factors for cerebrovascular disease. Transl Res 2007; 150: 158-63. [CrossRef]